The great challenge that has arisen in the process of vaccination against coronavirus around the world has been the variants that have raised doubts about the effectiveness of the pricks and that in fact, may force pharmaceutical companies to review their formulated. But in a year this matter can be solved.
As collected by the Mirror, scientists say a ‘universal vaccine’ effective against all variants of Covid-19 could be available by the end of the year.
Researchers are developing injections that they target the core of the virus, instead of spike protein, and they believe it could end the need to modify existing doses. The new vaccine is being developed at the University of Nottingham.
Currently approved vaccines target spike protein, but are likely to become less effective as Covid-19 mutates, meaning people are likely to require ‘recharge’ punctures in the future.
The British Pharmaceutical Company Scancell is among the companies researching universal vaccines. Trials in mice have been encouraging and human trials are expected in the second half of this year.
Scancell’s medical director, Dr. Gillies O’Bryan-Tear, said: “We are not necessarily claiming that it will be a pan-coronavirus vaccine, but it has the potential to be simply because of where it is going.”
However, researchers have urged people to be careful not to be overly optimistic, as A universal flu vaccine has never been developed.
Immunologist from Imperial College, Professor Danny Altmann, an immunologist at Imperial College, said: “There is no reason why, if we get a partner, we can’t do it as fast as everyone else.”
Professor Altmann said he believes the pandemic will last “two or three more years” because of the time it will take for developing countries to vaccinate their populations.
Also in the United States
But it is not only in the United Kingdom that they are working on the universal vaccine against all coronaviruses. U.S he is also in it, as the prestigious New York newspaper collects The New York Times.
Kayvon Modjarrad, director of the Emerging Infectious Diseases Branch at the Walter Reed Army Research Institute in Silver Spring, Maryland, is one of many scientists who for years have been calling for a different type of vaccine: one that could work against all coronaviruses.
The doctor Eric Topol, A professor of molecular medicine at the Scripps Research Institute in San Diego, he believes scientists should join together on another large-scale vaccine creation project right away. “We have to get a real workforce to accelerate this, so we can have it this year.”
Last month, Pamela bjorkman, a structural biologist at Caltech, and her colleagues published a more extensive experiment with a universal coronavirus vaccine in the journal Science. The researchers attached just the tips of the proteins from eight different coronaviruses to a protein core, known as a nanoparticle. After injecting these nanoparticles into mice, the animals generated antibodies that could adhere to the eight coronaviruses and four other coronaviruses that scientists hadn’t used in the vaccine.
And Dr. Hoft from Saint Louis University, is working on a universal vaccine that does not depend on antibodies against the spike protein. In collaboration with Gritstone Oncology, a California-based biotechnology company, they have created a vaccine that prompts cells to produce surface proteins that could alert the immune system as if a coronavirus, any coronavirus, were present. Now they are preparing a clinical trial to see if it is effective against SARS-CoV-2.